Detalhe da pesquisa
1.
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Proc Natl Acad Sci U S A
; 114(7): E1072-E1080, 2017 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28137841
2.
Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Mol Cancer Ther
; 19(3): 755-764, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31974273
3.
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Mol Cancer Ther
; 18(6): 1036-1044, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31018997
4.
Association of high microvessel αvß3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.
Oncotarget
; 8(32): 52193-52210, 2017 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881723
5.
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Mol Cancer Ther
; 15(11): 2553-2562, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27496136
6.
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
PLoS One
; 11(3): e0150836, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26938241
7.
Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
J Med Chem
; 56(5): 1922-39, 2013 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23410005
8.
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
Cancer Chemother Pharmacol
; 71(4): 867-81, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23355037
9.
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Cancer Res
; 68(1): 206-15, 2008 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18172313